• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA to review pSivida’s ocular drug-delivery system

March 20, 2018 By Sarah Faulkner

pSivida DurasertpSivida (NSDQ:PSDV) said yesterday that the FDA plans to review the company’s application for its drug-releasing ocular insert, Durasert. The product is designed to provide three years of treatment for patients with posterior segment uveitis.

The U.S. regulatory agency is slated to decide whether or not to approve pSivida’s new drug application by Nov. 5.

“The FDA’s acceptance for review of our Durasert NDA submission is a major milestone for pSivida and we look forward to continuing to work with the FDA as they review our application,” president & CEO Nancy Lurker said in prepared remarks.

The Watertown, Mass.-based company’s NDA included data from two successful late-stage trials, including a 153-patient Phase III trial that found there was a significant reduction in the recurrence of posterior segment uveitis through 12 months in the group treated with pSivida’s tiny, drug-releasing ocular insert.

Just 37% of people treated with Durasert experienced a recurrence compared to 71.2% of patients in the control group, pSivida reported last month. The portion of patients who required medication to lower their intraocular pressure during the 12 months of follow-up was 50.5% for the Durasert group and 51.9% for the control group. Just one patient, who was treated with Durasert, needed IOP surgery.

“Given the high unmet medical need, we believe that Durasert, if approved, has the potential to become an important new treatment option for the thousands of patients suffering from posterior segment uveitis, the third leading cause of blindness,” Lurker added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: pSivida Corp.

IN CASE YOU MISSED IT

  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS